Carvone derived cannabidiol enantiomers as novel anticonvulsants
Developmental epilepsy syndromes are characterized by recurrent seizures and developmental delays. Current anticonvulsants target γ-aminobutyric acid type A receptor signaling
Tag: epilepsy
Marinus Announces FDA Acceptance for Filing and Priority Review of NDA for SBECD-enabled Ganaxolone in CDKL5 Deficiency Disorder
Marinus Pharmaceuticals, Inc. , a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, announced that
Marinus Pharmaceuticals and Orion Corporation agree on Commercialization of SBECD-enabled Ganaxolone
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, announced that
Marinus Pharmaceuticals Provides SBECD-enabled Ganaxolone Clinical Data
Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, announced it
Sedor Pharmaceuticals Receives FDA Approval for SESQUIENT™ (SBECD-enabled fosphenytoin)
Ligand Pharmaceuticals Incorporated announced that its partner Sedor Pharmaceuticals, LLC has received approval from the U.S. Food and Drug Administration
Marinus Awarded BARDA Contract to Develop SBECD-enabled Ganaxolone for Treatment of Refractory Status Epilepticus
Marinus Pharmaceuticals, a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, announced it has
Marinus Data from SBECD-enabled Ganaxolone Phase 2 Trial in Refractory Status Epilepticus
Marinus Pharmaceuticals, Inc. a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy, depression and other neuropsychiatric
Positive Results With SBECD-enabled Ganaxolone in Phase 2 Refractory Status Epilepticus Trial
Marinus Pharmaceuticals, a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy, depression and other neuropsychiatric disorders,